Project Term: February 28, 2021 - TBD
In February 2021, LLS made an equity investment in Caribou Biosciences to "Support allogeneic BCMA CAR development for multiple myeloma." LLS is supporting the preclinical development of CB-011, Caribou’s second allogeneic CAR-T cell therapy, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma (MM). It is the first allogeneic CAR-T cell therapy immune-cloaked to prevent both T- and NK-mediated immune rejection. Caribou's immune cloaking strategy is expected to drive CAR-T cell persistence, enabling more durable antitumor activity.
For additional information, please visit https://lls.org/therapy-acceleration-program-portfolio